Sana Biotechnology (SANA) Gains from Sales and Divestitures (2021 - 2026)
Sana Biotechnology recorded quarterly Gains from Sales and Divestitures of $864000.0 in Q1 2026, down 42.97% quarter-over-quarter from $1.5 million in Q4 2025, and down 10.0% year-over-year from $960000.0 in Q1 2025.
Sana Biotechnology's Gains from Sales and Divestitures history runs 6 years deep, the most recent figure standing at $864000.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures fell 10.0% year-over-year to $864000.0; the TTM figure through Mar 2026 stood at $864000.0 (down 10.0% YoY), while the FY2025 annual figure was $1.5 million, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $864000.0 for Q1 2026 at Sana Biotechnology, down from $1.5 million in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $4.3 million in Q4 2022 to a low of $14000.0 in Q1 2022.
- A 5-year average of $1.2 million and a median of $694000.0 in 2024 frame the typical range for Gains from Sales and Divestitures.
- Across the five-year window, Gains from Sales and Divestitures plunged 99.02% in 2022 and surged 950.0% in 2023, its largest moves.
- Sana Biotechnology's Gains from Sales and Divestitures stood at $4.3 million in 2022, then tumbled by 90.0% to $431000.0 in 2023, then climbed by 21.58% to $524000.0 in 2024, then jumped by 189.12% to $1.5 million in 2025, then tumbled by 42.97% to $864000.0 in 2026.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $864000.0, $1.5 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 864,000.00 |
| Mar 31, 2026 | 864,000.00 |
| Dec 31, 2025 | 1.52 Mn |
| Dec 31, 2025 | 1.52 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 960,000.00 |
| Mar 31, 2025 | 960,000.00 |
| Sep 30, 2024 | 524,000.00 |
| Sep 30, 2024 | 524,000.00 |
| Jun 30, 2024 | 440,000.00 |
| Jun 30, 2024 | 440,000.00 |
| Mar 31, 2024 | 388,000.00 |
| Mar 31, 2024 | 388,000.00 |
| Dec 31, 2023 | 431,000.00 |
| Dec 31, 2023 | 431,000.00 |
| Sep 30, 2023 | 342,000.00 |
| Sep 30, 2023 | 342,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Mar 31, 2023 | 147,000.00 |
| Mar 31, 2023 | 147,000.00 |
| Dec 31, 2022 | 4.31 Mn |
| Dec 31, 2022 | 4.31 Mn |
| Sep 30, 2022 | 3.53 Mn |
| Sep 30, 2022 | 3.53 Mn |
| Jun 30, 2022 | 2.63 Mn |
| Jun 30, 2022 | 2.63 Mn |
| Mar 31, 2022 | 14,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 5.69 Mn |
| Dec 31, 2021 | 5.69 Mn |
| Sep 30, 2021 | 4.27 Mn |
| Sep 30, 2021 | 4.27 Mn |
| Jun 30, 2021 | 2.85 Mn |
| Jun 30, 2021 | 2.85 Mn |
| Mar 31, 2021 | 1.43 Mn |
| Mar 31, 2021 | 1.43 Mn |